DXCM (DexCom) Ending Cash Position: $1,118 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DXCM DexCom Inc DXCM
94 GF Score
Price $72.73
GF Value $104.31
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is DexCom Ending Cash Position?

DexCom DXCM -1.88% 94 Ending Cash Position is $1,118 Mil as of Mar. 2026. GuruFocus rates DXCM with a GF Score™ of 94/100 and a GF Value™ of $104.31 (Significantly Undervalued). The stock has 3 warning signs investors should review.

DexCom's Ending Cash Position for the quarter that ended in Mar. 2026 was $1,118 Mil.

DexCom's quarterly Ending Cash Position declined from Sep. 2025 ($1,837 Mil) to Dec. 2025 ($919 Mil) but then increased from Dec. 2025 ($919 Mil) to Mar. 2026 ($1,118 Mil).

DexCom's annual Ending Cash Position increased from Dec. 2023 ($568 Mil) to Dec. 2024 ($607 Mil) and increased from Dec. 2024 ($607 Mil) to Dec. 2025 ($919 Mil).

DexCom Ending Cash Position Related Terms

DexCom Ending Cash Position Historical Data

* Premium members only.

The historical data trend for DexCom's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Ending Cash Position Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,053.60 643.30 567.50 607.30 919.10

DexCom Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 906.10 1,160.30 1,836.90 919.10 1,118.40
DXCM
94GF Score
DexCom Inc DXCM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

DexCom's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=607.3+311.8
=919

DexCom's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=919.1+199.3
=1,118

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1,118 Mil mean?
DexCom (DXCM) has a Ending Cash Position of $1,118 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DexCom and its competitors.
Is DexCom's Ending Cash Position too high?
DexCom's current Ending Cash Position is $1,118 Mil. Overall, DexCom has a GF Score™ of 94/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Ending Cash Position compare to GEHC and STE?
DexCom's Ending Cash Position of $1,118 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DexCom and its competitors. DexCom's current Ending Cash Position is $1,118 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Significantly Undervalued. The stock's GF Value™ is $104.31, compared to a current price of $72.73 — trading 30.3% below its estimated fair value. The current Ending Cash Position is $1,118 Mil. DexCom's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For DexCom (DXCM), the current Ending Cash Position is $1,118 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of $72.73 is trading 30.3% below its estimated GF Value™ of $104.31. GuruFocus considers DexCom to be Significantly Undervalued.

Key valuation signals for DXCM:

  • Ending Cash Position: $1,118 Mil
  • GF Value™: $104.31 vs. price of $72.73 (30.3% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
94GF Score

Get the complete analysis for DXCM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$72.73
Price
$104.31
GF Value